![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Chris Rivera
Rivera has more than 30 years of experience in the biotechnology industry. He was founder and CEO of Hyperion Therapeutics, which was acquired by Horizon Pharma; and Senior Vice President at both Tercica and Genzyme Therapeutics, where he helped launch Genzyme’s renal division. Prior to Genzyme, he helped build Cephalon’s and Centocor’s initial commercial infrastructures.
Before joining Nativis, Rivera was the President and CEO of Life Science Washington, the state’s life science trade association.Rivera holds a master’s degree from the University of Oklahoma Health Sciences Center; a bachelor’s degree from Northwestern Oklahoma State University; and studied marketing and management at the Albers Graduate School of Business and Economics at Seattle University.
Company:Nativis Inc
Nativis is a Seattle-based clinical stage therapeutic device company whose patented, groundbreaking technology utilizes precisely targeted, ultra-low radio frequency energy (ulRFE®) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use, non-invasive investigational device. The company’s goal is to transform disease treatment on a global scale with ulRFE, which can potentially be applied to a wide range of health-related needs. Nativis’ initial focus is on the treatment of patients with brain cancer (initially, glioblastoma), with additional pre-clinical work being undertaken for lung and other cancers, inflammatory disease and chronic pain.
